Your browser is no longer supported. Please, upgrade your browser.
Settings
AVDL [NASD]
Avadel Pharmaceuticals plc
Index- P/E- EPS (ttm)-0.18 Insider Own0.10% Shs Outstand58.44M Perf Week-1.92%
Market Cap469.09M Forward P/E- EPS next Y-0.16 Insider Trans0.00% Shs Float35.64M Perf Month-6.68%
Income-5.60M PEG- EPS next Q-0.31 Inst Own58.10% Short Float11.86% Perf Quarter-21.39%
Sales10.10M P/S46.44 EPS this Y95.70% Inst Trans1.60% Short Ratio16.20 Perf Half Y10.82%
Book/sh2.34 P/B3.28 EPS next Y86.80% ROA-1.70% Target Price- Perf Year-5.07%
Cash/sh3.38 P/C2.27 EPS next 5Y15.00% ROE-3.40% 52W Range4.83 - 10.32 Perf YTD14.97%
Dividend- P/FCF- EPS past 5Y-15.30% ROI3.00% 52W High-24.07% Beta1.32
Dividend %- Quick Ratio- Sales past 5Y-33.60% Gross Margin67.40% 52W Low62.32% ATR0.40
Employees32 Current Ratio26.60 Sales Q/Q-100.00% Oper. Margin- RSI (14)48.49 Volatility3.29% 5.76%
OptionableYes Debt/Eq0.00 EPS Q/Q5.40% Profit Margin-55.00% Rel Volume0.65 Prev Close7.68
ShortableYes LT Debt/Eq1.04 EarningsMay 10 BMO Payout- Avg Volume260.84K Price7.84
Recom1.40 SMA200.58% SMA50-2.95% SMA2008.40% Volume60,139 Change2.08%
Jul-31-20Initiated Oppenheimer Outperform $19
Jul-21-20Initiated SVB Leerink Outperform $17
Jun-30-20Initiated H.C. Wainwright Buy $15
Apr-03-20Initiated Jefferies Buy $14
Mar-12-20Initiated Stifel Buy $14
Feb-26-20Initiated Piper Sandler Overweight $14
Jan-30-20Initiated Craig Hallum Buy $15
Jun-14-19Upgrade Ladenburg Thalmann Neutral → Buy $6
Feb-08-19Downgrade Ladenburg Thalmann Buy → Neutral
Jun-09-21 09:00AM  
Jun-03-21 08:00AM  
Jun-02-21 08:00AM  
May-25-21 08:00AM  
May-13-21 02:00AM  
May-10-21 06:00PM  
08:00AM  
06:45AM  
Apr-29-21 08:00AM  
Apr-19-21 07:05AM  
Apr-17-21 08:00AM  
Apr-08-21 08:00AM  
Mar-29-21 01:22AM  
Mar-18-21 08:00AM  
Mar-09-21 03:00PM  
07:00AM  
05:30AM  
Mar-04-21 08:00AM  
Mar-02-21 08:00AM  
Mar-01-21 12:10PM  
08:00AM  
Feb-25-21 08:00AM  
Feb-23-21 06:20PM  
Feb-17-21 08:00AM  
Feb-10-21 08:00AM  
Dec-28-20 11:47PM  
Dec-16-20 02:21PM  
08:00AM  
Dec-15-20 08:00AM  
Dec-07-20 08:00AM  
Nov-23-20 08:00AM  
Nov-11-20 08:00AM  
Nov-09-20 06:30PM  
07:00AM  
06:30AM  
Oct-26-20 08:00AM  
Oct-07-20 10:38AM  
Sep-30-20 06:58AM  
Sep-17-20 08:00AM  
Sep-14-20 08:00AM  
Sep-11-20 04:35PM  
Aug-18-20 08:42AM  
Aug-11-20 01:30AM  
Aug-10-20 08:34AM  
08:00AM  
Aug-05-20 03:31PM  
Aug-01-20 08:12AM  
Jul-27-20 08:00AM  
Jul-13-20 08:00AM  
Jul-03-20 07:05AM  
Jul-01-20 08:00AM  
Jun-27-20 09:13PM  
Jun-08-20 08:00AM  
Jun-01-20 09:20AM  
08:00AM  
May-28-20 05:54AM  
May-11-20 02:30PM  
10:17AM  
07:00AM  
May-09-20 08:10AM  
May-06-20 07:04AM  
May-04-20 04:05PM  
Apr-28-20 08:28PM  
12:55PM  
10:48AM  
07:36AM  
Apr-27-20 06:07PM  
04:20PM  
10:38AM  
07:00AM  
Apr-23-20 08:46AM  
Apr-15-20 09:23AM  
Apr-08-20 10:02AM  
Mar-25-20 08:00AM  
Mar-14-20 08:26AM  
Mar-13-20 06:56AM  
Mar-12-20 07:00AM  
06:30AM  
Mar-11-20 12:27PM  
Feb-27-20 08:30AM  
08:00AM  
Feb-21-20 09:00AM  
Jan-28-20 02:59AM  
Jan-23-20 10:42AM  
Jan-21-20 08:41AM  
Jan-13-20 05:26AM  
Jan-10-20 08:00AM  
Jan-06-20 12:00PM  
Dec-23-19 07:54AM  
Dec-19-19 11:15AM  
Dec-17-19 12:00PM  
08:00AM  
Dec-16-19 08:00AM  
Dec-15-19 03:49PM  
Dec-10-19 08:00AM  
Dec-09-19 10:04AM  
09:18AM  
Dec-06-19 03:07PM  
Dec-02-19 08:00AM  
Nov-29-19 08:13AM  
Avadel Pharmaceuticals plc operates as a biopharmaceutical company in the United States. The company's lead product candidate is FT218, a formulation of sodium oxybate which is in a Phase 3 clinical trial for the treatment excessive daytime sleepiness (EDS) and cataplexy in adults with narcolepsy. The company was formerly known as Flamel Technologies SA and changed its name to Avadel Pharmaceuticals PLC in January 2017. Avadel Pharmaceuticals plc was incorporated in 2015 and is headquartered in Dublin, Ireland.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
MCHUGH THOMAS SChief Financial OfficerSep 18Buy6.004,00024,00021,500Sep 21 04:01 PM
McCamish Mark AnthonyDirectorSep 17Buy5.8352,398305,250171,000Sep 18 04:20 PM
Ende Eric JDirectorSep 17Buy5.7917,00098,37684,900Sep 18 04:19 PM
McCamish Mark AnthonyDirectorSep 16Buy5.73118,602679,969118,602Sep 18 04:20 PM
MCHUGH THOMAS SChief Financial OfficerAug 28Buy6.777,50050,77617,500Sep 01 04:12 PM
Glass Geoffrey MichaelDirectorAug 28Buy6.784,80032,56065,700Sep 01 04:11 PM
Palczuk LindaDirectorAug 14Buy7.942,50019,85037,900Aug 17 06:58 PM
Glass Geoffrey MichaelDirectorAug 13Buy7.766,50050,44060,900Aug 14 06:11 PM
MCHUGH THOMAS SChief Financial OfficerAug 13Buy7.7810,00077,81410,000Aug 17 06:59 PM
Ende Eric JDirectorAug 13Buy7.795,00038,92867,900Aug 17 06:57 PM
Glass Geoffrey MichaelDirectorAug 12Buy7.706,50050,05054,400Aug 14 06:11 PM
Divis Gregory JChief Executive OfficerAug 12Buy7.7813,000101,15699,100Aug 13 07:39 PM
Ende Eric JDirectorAug 12Buy7.7615,000116,35562,900Aug 13 07:40 PM